EMSAM Drug Patent Profile

Which patents cover Emsam, and when can generic versions of Emsam launch?

Emsam is a drug marketed by Somerset and is included in one NDA.

The generic ingredient in EMSAM is selegiline. There are seventeen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the selegiline profile page.

Summary for EMSAM

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for EMSAM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Somerset	EMSAM	selegiline	FILM, EXTENDED RELEASE;TRANSDERMAL	021336-001	Feb 27, 2006		RX	Yes	Yes
Somerset	EMSAM	selegiline	FILM, EXTENDED RELEASE;TRANSDERMAL	021336-002	Feb 27, 2006		RX	Yes	No
Somerset	EMSAM	selegiline	FILM, EXTENDED RELEASE;TRANSDERMAL	021336-003	Feb 27, 2006		RX	Yes	No

International Patents for EMSAM

See the table below for patents covering EMSAM around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	628340
Hungary	T55221
Canada	1329132	METHODE D'ADMINISTRATION DU DEPRENYL, PERMETTANT DE REDUIRE AU MINIMUM LES EFFETS SECONDAIRES DU PRODUIT (METHOD FOR ADMINISTERING THE DRUG DEPRENYL SO AS TO MINIMIZETHE DANGER OF SIDE EFFECTS)
China	1048320
Australia	3502289

EMSAM Market Analysis and Financial Projection

Last updated: February 3, 2026

What Is EMSAM and Its Market Context?

EMSAM (selegiline transdermal system) is a prescription medication used primarily for the treatment of major depressive disorder (MDD). It delivers the monoamine oxidase inhibitor (MAOI) via a transdermal patch, designed to minimize dietary restrictions and side effects associated with older oral MAOIs. EMSAM was approved by the FDA in 2006 but faced limited commercial success.

The global antidepressant market was valued at approximately $18.6 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 2.3% from 2022 to 2028. Industry players include Pfizer (original developer), Lundbeck, and generic manufacturers, with newer agents like SSRIs and SNRIs dominating market share.

What Are the Key Drivers and Challenges for EMSAM Investment?

Market Penetration and Competitor Landscape

• Limited Adoption: EMSAM's complex application, higher cost, and side effect profile compared to SSRIs have constrained market penetration.
• Competitive Alternatives: SSRIs (e.g., fluoxetine, sertraline) dominate depression treatment due to ease of use and safety profile, reducing the demand for MAOIs.
• Niche Positioning: EMSAM is positioned for treatment-resistant depression (TRD) or patients intolerant to SSRIs, but data on TrD efficacy remains limited.

Clinical and Regulatory Fundamentals

• Efficacy Profile: Demonstrates efficacy comparable to oral MAOIs, with a safety profile requiring monitoring due to hypertensive crisis risk if dietary restrictions are not observed.
• Regulatory Status: No recent label updates or expanded indications; the FDA maintains specific warnings, impacting growth prospects.
• Patent Protection: No active patents protecting EMSAM, exposing potential for generic competition post-market exclusivity.

Financial and Developmental Aspects

• Sales Performance: Peak sales were approximately $52 million in 2008, with declining or stagnant figures since then due to limited adoption.
• Pipeline Developments: No significant pipeline developments or reformulations announced, limiting future revenue potential.

Socioeconomic and Policy Environment

• Pricing and Reimbursement: Higher priced than oral generics, facing reimbursement challenges.
• Healthcare Policy: Growing emphasis on mental health but constrained budgets and preference for widely adopted drugs limit EMSAM's growth.

What Investment Fundamentals Exist for EMSAM?

Aspect	Data/Details	Implication
Market Size	$18.6B global antidepressant market (2021)	Large overall market but limited EMSAM-specific share
Market Growth	2.3% CAGR (2022–2028)	Slight growth; niche positioning for EMSAM may limit share
Revenue Trend	~$52M peak sales (2008); declining since	Limited revenue prospects unless new indications emerge
Patent & Exclusivity	No patents; potential generic competition post-approval	Future revenue restricted; price erosion risk
Competition	SSRIs/SNRIs occupy significant market share	EMSAM faces competition from well-established, easier options
Pricing & Reimbursement	Higher price; reimbursement challenges	Affords limited use; affects sales volume

What Are the Key Investment Risks and Opportunities?

Risks

• Market Share Erosion: Increasing generic availability and competition reduce revenue prospects.
• Limited Clinical Expansion: No new indications or formulations projected, constraining growth.
• Pricing Constraints: Reimbursement policies favor lower-cost alternatives, impacting profitability.

Opportunities

• Niche Demands: Potential growth within treatment-resistant depression populations if targeted appropriately.
• Combination Therapy: Possible utility in combination regimens remains unexplored.
• Policy Shifts: Increased focus on mental health may create indirect demand, though price sensitivity remains high.

Final Analysis

EMSAM represents a niche therapeutic with limited growth prospects driven by intense market competition, loss of exclusivity, and a small user base. Its valuation should reflect minimal revenue potential absent significant market expansion or clinical breakthroughs.

Key Takeaways

• EMSAM's market penetration is constrained by existing competition and clinical preferences.
• Its sales peaked early and have declined, with current revenue estimates below $10 million.
• No active patent protections or pipeline advancements hinder future growth.
• The key investment interest centers on niche applications, such as treatment-resistant depression, which have limited market size.
• Risks associated with competition and reimbursement policies outweigh the potential for substantial upside.

FAQs

Q1: Is EMSAM considered a viable investment for revenue growth?
No, current data suggest limited growth potential due to market saturation, competition, and lack of pipeline development.

Q2: Could new formulations or indications enhance EMSAM’s market share?
Potentially, but no such developments are currently announced, and regulatory hurdles would need to be addressed.

Q3: How does EMSAM compare to other antidepressants in terms of safety?
It has a distinct safety profile requiring dietary restrictions, unlike SSRIs and SNRIs, which have broader safety margins.

Q4: What is the likelihood of generic competition?
Since there are no active patents, generic versions could enter the market once exclusivity expires, likely within the next few years.

Q5: Are there regulatory barriers that could inhibit EMSAM’s market expansion?
The FDA maintains warnings and restrictions on MAOIs, which limit market appeal and expansion possibilities.

---

References

[1] MarketsandMarkets. Antidepressant Market Forecast 2022-2028.
[2] FDA. EMSAM (selegiline transdermal system) approval history.
[3] IQVIA. Global Prescription Drug Market Data.
[4] Pfizer. Corporate filings and sales disclosures.